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Summary
Background: Although combination therapy for various cardiac conditions with dual antiplatelet
therapy (aspirin and thienopyridine derivatives) and warfarin sodium has become increasingly
popular, the safety and effectiveness of this aggressive treatment regimen remain unknown.
Methods and results: We retrospectively enrolled and analyzed 575 consecutive patients who
had been implanted with drug-eluting coronary stents. The primary and secondary endpoints
were major bleeding complications and major adverse cardiovascular events (MACE), respec-
tively. At the time of discharge, 525 patients (91.3%) were prescribed with dual antiplatelet
therapy, and 50 (8.7%) of them received dual antiplatelet plus anticoagulant therapy (triple
therapy). The patients treated with triple therapy had a greater prevalence of comorbid condi-
tions, including left ventricular systolic dysfunction and multi-vessel coronary disease compared
to those on the dual antiplatelet regimen. During a median follow-up of 459 days, 14 (2.7%)
patients receiving dual, and 9 (18.0%) receiving triple therapy reached the primary endpoint
(p < 0.001). These results show that warfarin use was associated with an increased risk of sub-
sequent major bleeding. On the other hand, the incidence of MACE did not differ between the
two groups (p = 0.108 by the log-rank test). Multivariate analysis showed that renal impairment
was an independent predictor of the risk of subsequent major bleeding in the triple therapy
group.
Conclusions: Triple therapy increased the hemorrhagic complications in patients after percu-
taneous coronary intervention with drug-eluting stents, especially in patients with impaired
renal function. Great caution should be taken with patients who necessitate the addition of
anticoagulation therapy with warfarin to dual antiplatelet therapy.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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Introduction
Dual antiplatelet therapy with aspirin and thienopyridine
derivatives (either ticlopidine or clopidogrel) is standard for
care of patients undergoing percutaneous coronary inter-
vention (PCI) with drug-eluting stents (DES) [1,2]. The
recommended therapeutic period of the dual antiplatelet
regimen varies. To reduce the risk of late stent thrombosis,
dual antiplatelet therapy should be continued for the ﬁrst
12 months following a presentation with DES implantation,
but further continuation is desirable [2—4].
Although dual antiplatelet therapy after DES implanta-
tion is recommended [5,6], dual antiplatelet therapy with
an anticoagulant regimen is not, except for patients at high
risk of systemic or venous thromboembolism. The numbers
of patients eligible for anticoagulation therapy with war-
farin have increased because it has been recommended to
treat atrial ﬁbrillation, prosthetic heart valves, left ventric-
ular mural thrombus, venous thromboembolism, and other
conditions. Anticoagulation with warfarin sodium is par-
ticularly recommended to reduce the risk of stroke and
thromboembolic events in high-risk patients with nonva-
lvular atrial ﬁbrillation [7]. Thus, combinations of dual
antiplatelet therapy (aspirin with thienopyridine deriva-
tives) plus warfarin are increasingly being administered
after PCI to treat various cardiac conditions. Both anticoagu-
lation and dual antiplatelet therapies might help to prevent
systemic thromboembolism and stent thrombosis, although
increased hemorrhagic risk is associated with such therapy.
Moreover, a recent prospective, observational study [8] has
demonstrated that dual antithrombotic therapy with war-
farin plus an antiplatelet agent is independently related to
an increased risk of bleeding among Japanese patients. The
management of high-risk patients has frequently been left
to the discretion of individual physicians, because manage-
ment protocols have not been standardized [9—11].
The present study evaluates the risks and beneﬁts of dual
antiplatelet plus anticoagulant therapy in patients after PCI
with DES.
Methods
Study population
We retrospectively enrolled and analyzed 575 consecutive
patients who underwent successful PCI with DES at our insti-
tute between August 2004 and March 2007.
Stents were deployed using standard interventional
techniques via the femoral or radial approach after
an intravenous infusion of heparin (5000U). Aspirin and
thienopyridine derivatives (ticlopidine or clopidogrel) were
started at least two days before elective stenting. Aspirin
(at least 100mg per day) was started at 48 h before the
procedure and continued indeﬁnitely. A loading dose of
clopidogrel (300mg) was administered 48 h before the pro-
cedure, followed by 75mg daily. Alternatively, treatment
with ticlopidine (300mg) was started two days before
the procedure and continued thereafter. Loading doses of
each antiplatelet agent were prescribed immediately before
urgent PCI. Procedural success was deﬁned as residual steno-
sis of <30% by visual determination in the presence of
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hrombolysis In Myocardial Infarction (TIMI) ﬂow grade 3
ithout death, occurrence of Q wave myocardial infarc-
ion, or coronary artery bypass grafting. Serum creatinine
alues were measured at baseline. Estimated glomerular ﬁl-
ration rates (eGFR) were evaluated using the 4-variable
impliﬁed Modiﬁcation of Diet in Renal Disease (MDRD) equa-
ion [12]. Impaired renal function was deﬁned as an eGFR of
60ml/min/1.73m2.
All patients were prescribed with dual antiplatelet ther-
py with 81 or 100mg of aspirin, and 200mg of ticlopidine
r 75mg of clopidogrel once daily at discharge. Patients who
equired long-term anticoagulation therapy were prescribed
ith doses of warfarin sodium that were individualized to
aintain a prothrombin time international ratio (PTINR) of
.0 in addition to dual antiplatelet therapy.
The patients were assigned to the following groups
fter PCI: dual antiplatelet therapy (aspirin with thienopyri-
ine derivatives; dual therapy group), and dual antiplatelet
herapy plus warfarin sodium (aspirin with thienopyridine
erivatives plus warfarin sodium; triple therapy group).
hienopyridine derivatives for both groups were continued
or at least for nine months after PCI except if bleeding
ccurred.
ata collection and processing
linical data including demographic characteristics, risk fac-
ors, indications for PCI, indications for warfarin use and
reatment duration, angiographic parameters, and levels
f anticoagulation (based on PTINR) were collected from
atients’ records. We then compared the incidence of all
leeding episodes, thromboembolism, and clinical events
etween the two groups during follow-up.
eﬁnitions
he primary endpoint of this study was deﬁned as major
leeding complications occurring during follow-up. The
econdary endpoint was major adverse cardiovascular
vents (MACE), namely a composite of death, myocardial
nfarction, stent thrombosis, ischemia-driven target-lesion
evascularization, or stroke during follow-up.
As a general principle, any deﬁnition of major bleed-
ng needs to be based on objective criteria [13], and major
leeds are those that result in death, are life-threatening,
ause chronic sequelae, or consume major health-care
esources. Major bleeding is deﬁned herein as fatal bleed-
ng, symptomatic bleeding in a critical area or organ, such
s intracranial, intraspinal, intraocular, retroperitoneal,
ntraarticular or pericardial or intramuscular with com-
artment syndrome, a decrease in blood hemoglobin of
2.0 g/dl, or requirement for transfusion with two or more
nits of whole blood or red cells. Minor bleeding episodes
ncluded other hemorrhage that led to interruption of the
tudy medication.
Cardiovascular death included sudden death, fatal
yocardial infarction, fatal heart failure, cardiovascular
rocedure-related death, fatal stroke and other types of car-
iovascular death. Myocardial infarction was deﬁned as the
resence of at least two of the following: ischemic chest
ain, elevation of at least two cardiac markers of enzymes
troponin, creatine kinase, creatine kinase MB isozyme,
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Table 1 Baseline characteristics of study participants.
Whole cohort (n = 575) Dual antiplatelet
therapy (n = 525)
Dual antiplatelet
therapy plus warfarin
(n = 50)
p-Value
Age (years)a 66.0± 10.2 65.7± 10.3 68.6± 8.5 0.072
Gender, male (%) 486 (85%) 440 (84%) 46 (92%) 0.086
Diabetes (%) 295 (51%) 271 (52%) 24 (48%) 0.366
Hypertension (%) 423 (74%) 387 (74%) 36 (72%) 0.454
Hypercholesterolemiab (%) 384 (67%) 357 (67%) 27 (54%) 0.058
Current smoker (%) 154 (27%) 164 (31%) 10 (20%) 0.109
Acute myocardial infarction (%) 94 (13%) 88 (17%) 6 (12%) 0.227
Unstable angina (%) 131 (23%) 117 (22%) 14 (28%) 0.225
Left ventricular ejection fraction (%)a 53± 11 53± 11 46± 12 0.001
Multi-vessel coronary artery disease (%) 379 (66%) 338 (64%) 41 (82%) 0.007
Prior stroke (%) 60 (10%) 51 (10%) 9 (18%) 0.063
Prior bleeding complication (%) 20 (3%) 18 (3%) 2 (4%) 0.533
PTINRa 1.92± 0.37
Estimated glomerular ﬁltration ratea 79.3± 32.2 79.4± 32.5 77.4± 28.6 0.471
p-Values are for comparison of dual antiplatelet therapy vs. dual antiplatelet therapy plus warfarin. PTINR: prothrombin time interna-
dl.
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a Means± standard deviation.
b Hypercholesterolemia is deﬁned as total cholesterol ≥220mg/
ther cardiac enzymes) to at least twice the upper limit
f the normal reference range, and electrocardiographic
hanges compatible with myocardial infarction. Stroke was
eﬁned as an ischemic cerebral infarction caused by an
mbolic or thrombotic occlusion of a major intracranial
rtery. Stent thrombosis was diagnosed in the presence of
cute coronary syndrome with angiographic evidence of
ither thrombotic vessel occlusion or thrombus within the
tent.
tatistical analysis
ontinuous variables are presented as means (standard
eviations), and those distributed non-parametrically are
resented as medians. Discrete variables are presented
s frequencies (%). Continuous variables were compared
mong groups using the unpaired Student’s t-test and the
ann—Whitney U-test. Categorical variables were compared
sing the 2 test.
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Table 2 Adverse events during follow-up.
Whole cohort
(n = 575)
Dual a
thera
Total death 22 (3.8%) 18 (3.
Myocardial infarction 1 (0.2%) 1 (0.
Target vessel revascularization 46 (8%) 39 (7.
Stent thrombosis 0 (0%) 0 (0%
Overall bleeding 86 (15.0%) 66 (12
Major bleeding 24 (4.0%) 14 (2.
Minor bleeding 62 (10.8%) 52 (9.
Stroke 8 (1.4%) 6 (1.
Major adverse cardiovascular events 72 (12.5%) 61 (12
p-Values are for comparison of dual antiplatelet therapy vs. dual antipTo assess risk factors for the occurrence of cardiovas-
ular events, clinical factors were entered into univariate
nd multivariate analyses using the Cox proportional haz-
rds model. The cumulative proportions of event-free rates
ere calculated using the Kaplan—Meier analysis and differ-
nces in event-free rates were compared using the log-rank
est. A two-sided p-value of <0.05 was considered statisti-
ally signiﬁcant. Data were analyzed using SPSS System for
indows, version 11.13 (SPSS, Inc., Chicago, IL, USA).
esults
atients’ characteristicse enrolled 575 consecutive patients who underwent PCI
ith DES between August 2004 and March 2007. Anticoag-
lant therapy had been administered before PCI in 50 of
hem because of the following comorbidities: atrial ﬁbrilla-
ntiplatelet
py (n = 525)
Dual antiplatelet therapy
plus warfarin (n = 50)
p-Value
4%) 4 (8%) 0.115
2%) 0 (0%) 0.913
4%) 7 (14%) 0.07
) 0 (0%) 1.000
.8%) 20 (40%) <0.001
7%) 10 (20%) <0.001
9%) 10 (20%) 0.032
1%) 2 (4%) 0.993
%) 11 (22%) 0.034
latelet therapy plus warfarin.
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Table 3 Major bleeding complications.
Variable Dual antiplatelet
therapy (n = 525)
Dual antiplatelet therapy
plus warfarin (n = 50)
Fatal intracranial hemorrhage 2 (0.38%) 2 (4.0%)
Hemorrhagic shock 1 (0.19%) 2 (4.0%)
2 (0.38%) 6 (12.0%)
9 (1.7%) 0 (0%)
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subsequent major bleeding complications in the triple ther-
apy group (p = 0.04).Necessitating blood transfusion of ≥2 units
Gastrointestinal bleeding requiring surgical repair
tion (n = 29), coronary artery bypass grafting for those with
extensive anterior myocardial infarction (n = 8), left ven-
tricular mural thrombi (n = 5), prosthetic valve replacement
(n = 3), and a history of thromboembolism (n = 5). The base-
line clinical characteristics of the patients are shown in
Table 1. There were no signiﬁcant differences between two
groups except for left ventricular function and the preva-
lence of multi-vessel coronary artery disease. Mean left
ventricular ejection fraction was lower in the patients on
triple, than dual therapy (46± 12% vs. 53± 11%). Prevalence
of multi-vessel coronary artery disease was higher among
patients on triple, than dual therapy (82% vs. 64%).
Clinical outcomes
Patients returned for follow-up visits at one, three, and six
months and every three months thereafter. Further follow-
up was conducted by telephone every six months, and
medical records were examined to verify endpoints for all
participants. Follow-up continued until February 29, 2008
for all patients (follow-up rate, 100%; follow-up period,
459± 354 days). The events reported during follow-up are
listed in Table 2. During follow-up period, myocardial infarc-
tion and stent thrombosis were infrequent, and the rates
were similar in the two treatment groups. The incidence
of target vessel revascularization also did not signiﬁcantly
differ between the two groups. The incidence of bleed-
ing complications was recognized. Bleeding complications
arose in 14.8%, and the rates of major and minor bleeding
events were 4.0% and 10.8%, respectively. The incidence of
bleeding complications was higher in the patients on triple,
than dual antiplatelet therapy (38.0% vs. 12.8%, p < 0.001).
Moreover, the incidence of major bleeding was signiﬁcantly
higher in patients on triple than dual antiplatelet ther-
apy (18.0% vs. 2.7%, p < 0.001). Table 3 shows a further
breakdown of major bleeding complications. Major bleed-
ing complications were seen more frequently in the triple
therapy group (Table 3).
Overall (Fig. 1) and major (Fig. 2) bleeding was signiﬁ-
cantly increased among patients who were prescribed triple
therapy at discharge compared to those on dual therapy
(p < 0.001). On the other hand, the incidence of MACE did
not signiﬁcantly differ between the two groups (p = 0.108 by
the log-rank test; Fig. 3).Predictive values
Multivariate analysis showed that warfarin use and renal
impairment (eGFR <60ml/min/1.73m2) were independently
and signiﬁcantly correlated with subsequent major bleed-
F
iigure 1 Cumulative event-free survival from overall bleed-
ng in patients on dual and triple therapy.
ng complications (Table 4). However, warfarin use did
ot correlate with MACE (p = 0.096). Multi-vessel coronary
rtery disease (p = 0.025) and impaired renal function (eGFR
60ml/min/1.73m2; p = 0.007) were independent predic-
ors of MACE (Table 5).
The univariate and multivariable associations between
linical variables and subsequent major bleeding compli-
ations among the patients are shown in Table 6. After
ontrolling for other baseline factors, the variable describ-
ng impaired renal function was the strongest predictor ofigure 2 Cumulative event-free survival from major bleeding
n patients on dual and triple therapy.
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National Cardiovascular Data Registry [26]. Subsequently,igure 3 Cumulative event-free survival from major adverse
ardiovascular events in patients on dual and triple therapy.
iscussion
espite the impairment of cardiac function and the greater
revalence of multi-vessel coronary disease in the patients
reated with the triple antithrombotic regimen, this ther-
py was associated with comparable effects on prognosis
o those of dual antiplatelet therapy. On the other hand,
riple therapy was associated with an increase in bleeding
omplications compared to the standard dual antiplatelet
egimen. Renal impairment was an independent predictor
f major bleeding among the patients treated with triple
herapy.
Anticoagulant therapy with warfarin was superior to
he dual antiplatelet therapy in prevention of stroke in
atients with atrial ﬁbrillation [14,15], whereas warfarin
lus aspirin is less effective than ticlopidine plus aspirin
n preventing stent thrombosis in patients with coronary
l
t
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Table 4 Univariate and multivariate analyses of relationships be
Univariate
Hazard
ratio
95% CI p-Va
Age 1.06 1.014—1.115 0.0
Female gender 1.77 0.655—4.784 0.2
Diabetes 1.24 0.542—2.823 0.6
Hypertension 0.75 0.309—1.831 0.5
Hypercholesterolemia 0.50 0.222—1.145 0.1
Smoking 1.77 0.523—5.998 0.3
Left ventricular
ejection
fraction <40%
1.14 0.256—5.041 0.8
Multi-vessel
coronary artery
disease
3.35 0.991—11.335 0.0
Prior stroke 1.42 0.421—4.797 0.5
Warfarin use 8.74 3.824—19.988 <0.0
Impaired renal
functiona
3.39 1.487—7.739 0.0
a Estimated glomerular ﬁltration rate <60ml/min/1.73m2. CI: conﬁdY. Uchida et al.
rtery disease and coronary stent deployment [16—18]. Oth-
rs have demonstrated that dual antiplatelet therapy plus
arfarin increases the risk of bleeding [9,19—21]. To date,
onsensus has not been reached concerning pharmacother-
py for patients requiring long-term anticoagulant therapy
fter coronary stenting.
Rothberg et al. [22] demonstrated in a meta-analysis of
atients with acute coronary syndrome, that warfarin plus
spirin is associated with a decrease in the annual rate of
yocardial infarction, ischemic stroke, and revasculariza-
ion compared to aspirin alone. They concluded that the
ardiovascular beneﬁts of warfarin outweigh the bleeding
isks for patients with acute coronary syndrome who are at
ow or intermediate risk for bleeding. Karjalainen et al. [19]
uggested that dual antiplatelet therapy plus warfarin is cur-
ently the best option for most of such patients regardless of
he increased bleeding risk. Ruiz-Nodar et al. [23] reported
hat dual antiplatelet therapy plus warfarin reduces rates of
ortality and MACE in patients with atrial ﬁbrillation after
oronary stenting. Warfarin use was not associated herein
ith a substantial increase in major bleeding events.
Although left ventricular dysfunction has been associ-
ted with an increased risk of acute presentation of stent
estenosis [24], Nusca et al. [25] demonstrated the safety
f DES implantation in such patients. Despite the impair-
ent of cardiac function in patients treated with DES
mplantation and the triple antithrombotic regimen in the
resent study, this therapeutic modality was associated with
ffects on prognosis that were comparable to the stan-
ard dual antiplatelet regimen. The results of this study
re consistent with recently reported data from the USong-term dual antiplatelet therapy plus warfarin increases
he risk of bleeding and the beneﬁcial effects on progno-
is of high-risk patients might outweigh the potential risk of
arfarin.
tween baseline variables and subsequent major bleeding.
Multivariate
lue Hazard ratio 95% CI p-Value
12 1.04 0.987—1.098 0.14
6 2.22 0.765—6.424 0.14
1
3
04 0.73 0.315—1.685 0.46
6
7
52
7
01 8.02 3.335—19.151 <0.001
04 2.77 1.192—6.457 0.02
ence interval.
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Table 5 Univariate and multivariate analyses of the relation between baseline variables and major adverse cardiovascular
events.
Univariate Multivariate
Hazard ratio 95% CI p-Value Hazard ratio 95% CI p-Value
Age 0.99 0.976—1.023 0.96
Female gender 1.47 0.802—2.682 0.21 1.57 0.854—2.899 0.15
Diabetes 1.22 0.763—1.960 0.40
Hypertension 1.40 0.768—2.566 0.27 1.25 0.673—2.337 0.48
Hypercholesterolemia 0.76 0.467—1.234 0.26 0.77 0.464—1.273 0.31
Smoking 0.91 0.551—1.489 0.70
Left ventricular ejection
fraction <40%
1.11 0.469—2.630 0.81
Multi-vessel coronary
artery disease
2.07 1.153—3.731 0.015 1.97 1.089—3.576 0.025
Prior stroke 1.26 0.604—2.640 0.54
Warfarin use 2.01 1.054—3.821 0.034 1.74 0.907—3.353 0.096
3m2
f
M
s
O
l
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a
t
s
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SImpaired renal functiona 2.31 1.411—3.790
a deﬁned as estimated glomerular ﬁltration rate <60ml/min/1.7
As all patients underwent DES implantation in the present
study, they continued taking ticlopidine or clopidogrel for at
least nine months after PCI except if bleeding occurred.
Dual antiplatelet therapy with both aspirin and thienopy-
ridines is recommended for more than one month after bare
metal stent implantation. On the other hand, over three
and six months of dual antiplatelet therapy is required for
patients implanted with sirolimus- and paclitaxel-eluting
stents, respectively. The recommended therapeutic dura-
tion of dual antiplatelet therapy has recently varied in view
of the risk of late stent thrombosis and when possible,
it should be continued for 12 months after presentation
in patients with DES implants, but even further main-
tenance might be desirable [2—4]. Warfarin plus aspirin
is less effective than ticlopidine plus aspirin in prevent-
ing stent thrombosis [16,17,22]. The choice of DES in
stent implantation for patients in whom long-term antico-
agulation with warfarin is recommended requires special
attention.
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Table 6 Univariate and multivariate correlates of major bleeding
Univariate
Hazard ratio 95% CI
Age 1.11 1.012—1
Female gender 4.22 0.871—2
Diabetes 1.10 0.318—3
Hypertension 0.53 0.150—1
Hypercholesterolemia 0.54 0.151—1
Smoking 0.80 0.169—3
Left ventricular ejection fraction <40% 1.03 0.189—5
Multi-vessel coronary artery disease 0.44 0.111—1
Prior stroke 0.60 0.076—4
PTINR 3.11 0.609—1
Impaired renal functiona 4.28 1.234—1
a deﬁned as estimated glomerular ﬁltration rate <60ml/min/1.73m2
ratio.0.001 2.01 1.215—3.326 0.007
. CI: conﬁdence interval.
In this study, eGFR < 60ml/min/1.73m2 as well as war-
arin was an independent risk factor for major bleeding.
any reports have shown that chronic kidney disease con-
titutes a risk for the prognosis of ischemic heart disease.
ur data indicate that bleeding after PCI inﬂuences the like-
ihood of adverse outcomes in patients with impaired renal
unction. Moreover, we analyzed risk factors among patients
n dual antiplatelet therapy plus warfarin and multivariate
nalysis showed that an eGFR of <60ml/min/1.73m2 was
he only independent risk factor among such patients. The
tent and antithrombotic agents must be carefully selected
or patients with impaired renal function.
tudy limitationsome limitations are associated with the present study.
he ability to generalize the present ﬁndings is limited
ecause the study was a retrospective analysis at a single,
mall-volume center and was not randomized. Therefore,
in the patients with triple therapy.
Multivariate
p-Value Hazard ratio 95% CI p-Value
.221 0.03 1.10 0.984—1.228 0.09
0.393 0.07 1.10 0.131—9.129 0.99
.814 0.88
.882 0.53
.904 0.34
.823 0.78
.668 0.97
.711 0.23 0.39 0.083—1.841 0.24
.768 0.63
5.874 0.17 2.55 0.352—18.434 0.35
4.858 0.02 4.60 1.090—19.441 0.04
. CI: conﬁdence interval; PTINR: prothrombin time international
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[68
he results should be interpreted with caution. The patient
opulation might be skewed and several types of bias and
onfounders exist, although we minimized them using mul-
ivariate analysis. Renal function was evaluated by a single
reatinine measure. We could not determine whether par-
icipants who fulﬁlled the outcome criteria continued to do
o for at least three months. Regardless of these limitations,
e feel that our data may be applicable to indications for
ong-term anticoagulation among patients undergoing PCI.
onclusions
espite the impairment of cardiac function and the greater
revalence of multi-vessel coronary disease in the patients
n triple therapy, the effects on prognosis were similar
etween triple and standard dual antiplatelet therapies.
riple therapy increased the hemorrhagic complications in
atients after PCI with DES, especially in patients having
mpaired renal function. Great caution should be taken with
atients who necessitate the addition of anticoagulation
herapy with warfarin to dual antiplatelet therapy.
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